The value of C-11-5-hydroxy-tryptophan positron emission tomography in neuroendocrine tumor diagnosis and management: experience from one center

Nikolaou, A; Thomas, D; Kampanellou, C; Alexandraki, K; Andersson, LG; Sundin, A; Kaltsas, G

dc.contributor.author	Nikolaou, A	en
dc.contributor.author	Thomas, D	en
dc.contributor.author	Kampanellou, C	en
dc.contributor.author	Alexandraki, K	en
dc.contributor.author	Andersson, LG	en
dc.contributor.author	Sundin, A	en
dc.contributor.author	Kaltsas, G	en
dc.date.accessioned	2014-03-01T02:00:46Z
dc.date.available	2014-03-01T02:00:46Z
dc.date.issued	2010	en
dc.identifier.issn	0391-4097	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/29130
dc.subject	C-11-5-HTP-PET/CT	en
dc.subject	neuroendocrine tumors	en
dc.subject.classification	Endocrinology & Metabolism	en
dc.subject.other	SOMATOSTATIN RECEPTOR SCINTIGRAPHY	en
dc.subject.other	CARCINOID-TUMORS	en
dc.subject.other	ENDOCRINE TUMORS	en
dc.subject.other	PET	en
dc.subject.other	LOCALIZATION	en
dc.subject.other	MARKERS	en
dc.subject.other	ANALOG	en
dc.title	The value of C-11-5-hydroxy-tryptophan positron emission tomography in neuroendocrine tumor diagnosis and management: experience from one center	en
heal.type	journalArticle	en
heal.language	English	en
heal.publicationDate	2010	en
heal.abstract	Many neuroendocrine tumors (NET) are small and may escape localization by conventional imaging techniques. In such cases, C-11-5-hydroxy-tryptophan (C-11-5-HTP) positron emission tomography (PET) has been tested as an additional diagnostic tool. Nine patients with clinically, biochemically and/or histologically confirmed NET and negative computerized tomography (CT) or magnetic resonance imaging (MRI), and In-111-pentetreotide (Octreoscan) scintigraphy underwent imaging with C-11-5-HTP-PET/CT in order to: 1) detect the primary tumor lesion in three patients; 2) detect residual disease in two patients with appendiceal carcinoid, one with rectal carcinoid, one with midgut carcinoid, and one with ectopic ACTH secretion (EAS) due to residual pulmonary carcinoid; and 3) restage a patient with medullary thyroid carcinoma (MTC) and hepatic metastases. C-11-54HTP-PET/CT detected lesions in the mediastinum in a patient with EAS due to a pulmonary carcinoid, further hepatic metastases in a patient with carcinoid syndrome (CS) from a NET of unknown primary, further hepatic metastases in the patient with MTC, and hepatic metastases in the patient with midgut carcinoid. The C-11-5-HTP-PET/CT findings contributed to radical cure of the patient with recurrent EAS, and pointed towards bilateral adrenalectomy in the patient with EAS without evident primary tumor. In addition, C-11-5HTP-PET/CT directed towards combined surgical and medical treatment in the patient with CS and multiple rather than single hepatic metastases and in the patient with midgut carcinoid, and towards continuation of medical treatment in the patient with MTC. C-11-5-HTP-PET/CT is a useful imaging technique, providing additional information for the diagnosis, staging and decision-making regarding management of patients with NET. (J. Endocrinol. Invest. 33: 794-799, 2010) (C) 2010, Editrice Kurtis	en
heal.publisher	EDITRICE KURTIS S R L	en
heal.journalName	JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION	en
dc.identifier.isi	ISI:000287787900005	en
dc.identifier.volume	33	en
dc.identifier.issue	11	en
dc.identifier.spage	794	en
dc.identifier.epage	799	en